TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15658548
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1500 mg)
Study: 11293926
Drug: Orocal D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orocal D3 (500 mg calcium and 400 IU vitamin D3) taken in two doses at 6-hour intervals
Study: 11293926
Drug: Cacit vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cacit vitamin D3 (1000 mg calcium and 880 IU vitamin D3) taken as a single morning dose
Study: 8196849
Drug: Piroxicam FDDF
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam FDDF 20 mg/day
Study: 22461276
Drug: Noveon laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noveon laser treatment for onychomycosis
Study: 10726910
Drug: Bezafibrate treatment
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate treatment (16 weeks)
Study: 10726910
Drug: Bezafibrate treatment
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate treatment (8 weeks)
Study: 9292071
Drug: Topical all‐trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical all‐trans retinoic acid (RA)
Study: 9292071
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) followed by topical all‐trans retinoic acid (RA)
Study: 1606395
Drug: Intratracheal N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal N-acetylcysteine (5% N-acetylcysteine administered every 4 hours for one week)
Study: 1606395
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (administered every 4 hours for one week)
Study: 23136273
Drug: AAQ +
Normalized name: Abiraterone Acetate
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AAQ + AMX (artesunate amodiaquine with amoxicillin)
Study: 10235025
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with stem cell support (induction with cyclophosphamide and taxol, followed by three high dose cycles of carboplatin, taxol, etoposide, and melphalane)
Study: 10235025
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (as per AGO-Ovar-5-study)
Study: 9112171
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml MMC
Study: 9112171
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml MMC
Study: 30008787
Drug: Fermented Laminaria
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented Laminaria japonica (FST) 1.5 g/day for 6 weeks
Study: 25401715
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 to 20 mg/d)
Study: 18022546
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccines (including inactivated tumor cells, heat shock protein vaccines, anti-ganglioside antibodies)
Study: 31022313
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral therapy with exposure (CBT ERP)
Study: 26142612
Drug: Antidepressant continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant continuation (AD)
Study: 26142612
Drug: Antidepressant discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant discontinuation (C)
Study: 16208050
Drug: Modified Mini-Mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Mini-Mental State Examination (MMSE) administered to Group A (non-neurological illness)
Study: 16208050
Drug: Modified Mini-Mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Mini-Mental State Examination (MMSE) administered to Group B (encephalopathy)
Study: 10599952
Drug: Lidocaine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (600 mg + 5 microg/ml adrenaline)
Study: 10599952
Drug: Articaine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine (600 mg + 5 microg/ml adrenaline)
Study: 7867179
Drug: Control (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (medical therapy only, n = 33)
Study: 1784628
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg miglitol
Study: 22052170
Drug: Intensive timing
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive timing induction chemotherapy
Study: 22052170
Drug: Standard timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timing induction chemotherapy
Study: 22052170
Drug: Chemotherapy intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy intensification
Study: 23806850
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg subcutaneous progesterone daily for 11 days
Study: 23806850
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg subcutaneous progesterone daily for 11 days
Study: 21138376
Drug: Low-dose SBE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SBE (2,000 mg of SBE/day)
Study: 21138376
Drug: High-dose SBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SBE (4,000 mg of SBE/day)
Study: 21138376
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (1,140 mg of pinitol/day)
Study: 21138376
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (2,000 mg of lactose/day)
Study: 11866010
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg x kg(‐1) tobramycin once-daily
Study: 11866010
Drug: 3.3 mg
Normalized name: niacin 3.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mg x kg(‐1) tobramycin thrice-daily
Study: 2653044
Drug: Timolol 0.5%-Pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5%-Pilocarpine 4% twice a day
Study: 2653044
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice a day plus Pilocarpine 4% three times a day
Study: 134724
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (2 puffs, 0.02 mg per puff)
Study: 134724
Drug: Isoprenaline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (2 puffs, 0.1 mg per puff)
Study: 31454444
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy + Community Reinforcement Approach for Seniors (MET + CRA-S)
Study: 30768121
Drug: BFP excision
Normalized name: pNF1-Blast Excised
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFP excision with hydrodissection (15 mL of a vasoconstricting anesthetic solution)
Study: 30768121
Drug: BFP excision
Normalized name: pNF1-Blast Excised
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFP excision with 3 mL of lidocaine 2% with epinephrine
Study: 29154063
Drug: Silymarin (420mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (420mg divided into three equal 140-mg daily doses)
Study: 24684534
Drug: Methylphenidate 10
Normalized name: dexmethylphenidate 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 10 mg daily
Study: 14969841
Drug: Intramuscular matrine
Normalized name: matrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular matrine (100 mg daily for 90 days)
Study: 14969841
Drug: Conventional liver‐protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional liver‐protective drugs alone (control group)
Study: 11241028
Drug: Defined absorption
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined absorption regions of spectra
Study: 11241028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of four absorption regions (nu=CH, nu(as)CH(3), nuC-O (amide I), nuC-O (carbonyle))
Study: 9205679
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion without ibuprofen
Study: 9205679
Drug: Saline loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline loading after ibuprofen
Study: 7962396
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha injection
Study: 7962396
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group identified by serum progesterone values > 20 nmol/l and daily HCG changes > +50 IU/l/day
Study: 3304782
Drug: Human protamine
Normalized name: insulin lispro protamine, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human protamine sodium insulin 0.6 mg%
Study: 3304782
Drug: Human isophane
Normalized name: Human isophane insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human isophane zinc insulin
Study: 27012405
Drug: Omecamtiv Mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv Mecarbil (OM) high-dose cohort
Study: 25656094
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (healthy individuals)
Study: 25656094
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (healthy individuals)
Study: 23672380
Drug: Combination feedback
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination feedback (CB)
Study: 21039597
Drug: SRD441 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRD441 ointment
Study: 16625109
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium containing 300 mg of iodine (Iomeron 300) at a flow rate of 3.3 mL/s
Study: 16625109
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium containing 400 mg of iodine (Iomeron 400) at a flow rate of 2.5 mL/s
Study: 9424839
Drug: Rehabilitation complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen.
Study: 9424839
Drug: Rehabilitation complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation complex including 'dry' effervescent baths, magnetolaser therapy applied to the heart area, cryomassage of the abdomen, plus dry air baths.
Study: 3552295
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (35 mg acetylsalicylate per day for 7 days)
Study: 24389518
Drug: 150 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg·kg(‐1) body mass tyrosine (TYR)
Study: 20012918
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg alendronate once weekly (n = 23)
Study: 18686766
Drug: Group 5
Normalized name: Chlamydophila psittaci biogroup 5 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 5 - blood contaminated, no post-contamination treatment
Study: 8549578
Drug: Intense daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense daily isometric and isokinetic leg exercise
Study: 29855386
Drug: Early motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early motion and directed exercise (EMADE) intervention consisting of a non-weight-bearing progressive home exercise programme, complemented with manual therapy and education.
Study: 26691355
Drug: Preload (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload (10 ml/kg crystalloid before induction)
Study: 26691355
Drug: Coload (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coload (10 ml/kg crystalloid at the time of spinal anesthesia)
Study: 23402713
Drug: 1% milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% milk (44 kcal/100 ml)
Study: 23402713
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (44 kcal/100 ml)
Study: 23402713
Drug: Regular cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cola (44 kcal/100 ml)
Study: 21138519
Drug: Crushed lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed lanthanum 1000 mg 3 times daily
Study: 21138519
Drug: Chewed lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed lanthanum 1000 mg 3 times daily
Study: 17302877
Drug: Oestradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol (2 x 0.1 mg/day patches) for days 5-16
Study: 17302877
Drug: Combined Oestradiol
Normalized name: estradiol, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Oestradiol + Progesterone (200 mg/day for days 13-16)
Study: 11125410
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.05% mometasone furoate
Study: 9767545
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (trandolapril) + calcium antagonist (verapamil)
Study: 9767545
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (trandolapril)
Study: 3492487
Drug: Co-trimoxazole 960
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 960 mg
Study: 30172098
Drug: Initial invasive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial invasive strategy (cardiac catheterization and optimal revascularization plus optimal medical therapy)
Study: 30172098
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (optimal medical therapy alone)
Study: 26558626
Drug: Ramosetron (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3, 0.45, or 0.6 mg) administered as a single intravenous bolus 30 min before the end of surgery
Study: 26558626
Drug: Ramosetron (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (0.3, 0.45, or 0.6 mg)
Study: 20478446
Drug: Combination labial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination labial plus lingual infiltration of 4% articaine with 1:100,000 epinephrine
Study: 7691911
Drug: Theophylline (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (low concentration: 3.9 +/- 1.0 mg/liter)
Study: 7691911
Drug: Theophylline (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (medium concentration: 8.2 +/- 1.8 mg/liter)
Study: 7691911
Drug: Theophylline (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (high concentration: 13.2 +/- 2.3 mg/liter)
Study: 3101537
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 (0.6-1.0 mg)
Study: 25854014
Drug: Prozac group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prozac group (oral administration of prozac)
Study: 21042828
Drug: Clarithromycin 200
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 200 mg/day
Study: 16731542
Drug: Fixed appliances
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed appliances subsequent to rapid maxillary expansion (RME) and facemask therapy
Study: 11258645
Drug: Oral creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral creatine supplements (4 x 5 g per day)
Study: 9290397
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) doses (10, 20, 50, 100, 200, and 400 micrograms)
Study: 8322582
Drug: Naproxen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 0.5 g daily + Paracetamol 4 g daily
Study: 8322582
Drug: Naproxen 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1.0 g daily + Paracetamol 4 g daily
Study: 8322582
Drug: Naproxen 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1.5 g daily
Study: 8322582
Drug: Naproxen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 0.5 g daily
Study: 8322582
Drug: Naproxen 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 1.0 g daily
Study: 2426830
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion (0.5 to 2.0 mcg/kg/min i.v.)
Study: 16044037
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment principles
Study: 11955536
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered intravenously at weeks 0, 2, and 6
Study: 9536943
Drug: Mesalazine suppositories
Normalized name: mesalamine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine suppositories (Pentasa) 1 g three times a week
Study: 9536943
Drug: Mesalazine suppositories
Normalized name: mesalamine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine suppositories (Pentasa) 1 g/day for relapse
Study: 8585370
Drug: Imitation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imitation of therapy
Study: 2693026
Drug: R1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1 (50 mg/d, p. o; total dose: 18.25 g/yr/case)
Study: 2693026
Drug: R2 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2 (20 mg/d, p. o; total dose: 3.6 g/6mos/case)
Study: 2693026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (riboflavin 50 mg/d, p. o.)
Study: 558950
Drug: Chlorpromazine (CPZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ, 12.5 mg)
Study: 558950
Drug: Amobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amobarbital (100 mg)
Study: 28825853
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (NPBC) followed by platinum-based chemotherapy (PBC) at subsequent relapse (experimental arm)
Study: 28825853
Drug: Standard reverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reverse treatment sequence (control arm)
Study: 18511076
Drug: Overall (All
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (All Antidepressants)
Study: 16670691
Drug: B6 -50
Normalized name: vitamin B6 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: B6 -50 (50 mg vitamin B6 daily for 14 days)
Study: 16670691
Drug: B6 -100
Normalized name: vitamin B6 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: B6 -100 (100 mg vitamin B6 daily for 14 days)
Study: 9737359
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug plus thyroxine for 18 months
Study: 2498658
Drug: Theophylline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (10 mg per kilogram of body weight per day), administered orally for two months
Study: 2498658
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for two months
Study: 29654929
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health workers (CHWs) assisting patients with hypertension, using video narratives from patients who have controlled their BP through diet, exercise, and medication adherence. Participants met with CHWs 5 times (twice in person and three times telephonically).
Study: 22420423
Drug: Doxorubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin monotherapy
Study: 22420423
Drug: Epirubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin monotherapy
Study: 20216467
Drug: Carbohydrate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (25 g)
Study: 20216467
Drug: Protein (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (25 g)
Study: 2248076
Drug: Moclobemide (100‐350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (100‐350 mg daily)
Study: 2248076
Drug: Tranylcypromine (10‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (10‐30 mg daily)
Study: 6775209
Drug: Aminophylline (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (350 mg per tablet, 2 tablets)
Study: 6775209
Drug: Mixture (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture (75 mg theophylline, 112.5 mg diprophylline, 112.5 mg proxyphylline per tablet, 2 tablets)
Study: 6871070
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (8 cups/day for 4 weeks, 504 mg caffeine)
Study: 29866129
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g fat (Calogen®) per kg body weight orally
Study: 26751791
Drug: Epidural dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural dexmedetomidine (3 ml loading dose at 0.5 μg kg(‐1) and continuous 80 μg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Study: 26751791
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (3 ml loading dose at 0.03 mg kg(‐1) and continuous 4.5 mg in 150 ml levobupivacaine at 3 ml h(‐1) for two days)
Study: 10325486
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin gel
Study: 7782114
Drug: Pentamidine aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine aerosol (300 mg)
Study: 7782114
Drug: Pentamidine aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine aerosol + Roxithromycin (300 mg t.i.d.)
Study: 7782114
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg t.i.d.)
Study: 6781659
Drug: Photochemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photochemotherapy maintenance treatment once a week
Study: 6781659
Drug: Photochemotherapy maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photochemotherapy maintenance treatment once every three weeks
Study: 6781659
Drug: Regular maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular maintenance treatment